Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preliminary Evaluation of F-18 Rhodamine 6G in Healthy Individuals and Patients With Stable Heart Condition
NCT04528758Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2018
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of Rhodamine 6G in coronary artery disease (CAD) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Dosimetry. Started Oct 2018; status: completed.
02
Drugs
Rhodamine 6G
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04528758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04528758.